Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Печать: 0893-9675
ISSN Онлайн: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v20.i5-6.100
pages 373-390

Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer

Nalo Hamilton
UCLA School of Nursing, Los Angeles, CA; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA
Diana Marquez-Garban
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; Department of Medicine, Division of Hematology-Oncology, UCLA David Geffen School of Medicine, Los Angeles, CA
Vei H. Mah
Department of Human Genetics, University of California at Los Angeles, Los Angeles, CA 90095; Department of Medicine, Division of Hematology-Oncology, UCLA David Geffen School of Medicine, Los Angeles, CA
Yahya Elshimali
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
David Elashoff
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; Department of Medicine, Division of General Internal Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA
Edward B. Garon
Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA
Jaydutt Vadgama
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; Department of Medicine, Division of Cancer Research and Training, Charles Drew University School of Medicine and Science, Los Angeles, CA
Richard Pietras
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; Department of Medicine, Division of Hematology-Oncology, UCLA David Geffen School of Medicine, Los Angeles, CA

Краткое описание

Triple-negative breast cancers (TNBCs) lack estrogen receptor-α (ERα), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) amplification and account for almost half of all breast cancer deaths. This breast cancer subtype largely affects women who are premenopausal, African-American, or have BRCA1/2 mutations. Women with TNBC are plagued with higher rates of distant metastasis that significantly diminish their overall survival and quality of life. Due to their poor response to chemotherapy, patients with TNBC would significantly benefit from development of new targeted therapeutics. Research suggests that the insulin-like growth factor (IGF) family and estrogen receptor beta-1 (ERβ1), due to their roles in metabolism and cellular regulation, might be attractive targets to pursue for TNBC management. Here, we review the current state of the science addressing the roles of ERβ1 and the IGF family in TNBC. Further, the potential benefit of metformin treatment in patients with TNBC as well as areas of therapeutic potential in the IGF-ERβ1 pathway are highlighted.


Articles with similar content:

Role of the Progesterone Receptor (PR) and the PR Isoforms in Breast Cancer
Critical Reviews™ in Oncogenesis, Vol.13, 2007, issue 4
Orla Mc Cormack, Michael J. Kerin, Amanda McCann, Michele Harrison
Targeted Molecular Therapeutic Options for Hepatocellular Carcinoma
Critical Reviews™ in Oncogenesis, Vol.25, 2020, issue 1
Latha Neerukonda, Bassam Ghabach, Ishna Sharma, Kalyani Narra, Swathi Sridhar, Riyaz Basha, Umesh T. Sankpal
Glioblastoma Multiforme: The Genetic Perspective of the Treatment Planning
Critical Reviews™ in Eukaryotic Gene Expression, Vol.25, 2015, issue 4
Rasime Kalkan
Biomarkers of DNA Repair and Related Pathways: Significance of Treatment in Triple-Negative Breast Cancer
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 5-6
Wenwen Guo, Xue He, Congyang Wang, Nannan Chen, Yan Wang, Fengxia He, Li Lin
Hypoxia Is the Driving Force Behind GBM and Could Be a New Tool in GBM Treatment
Critical Reviews™ in Eukaryotic Gene Expression, Vol.25, 2015, issue 4
Rasime Kalkan